Our findings are consistent with previous observations in patients treated with tocilizumab, another IL-6Rα inhibitor, and suggest that IL-6 pathway inhibition leads to decreased UDP-glucuronosyltransferase 1-1 activity in Gilbert’s syndrome patients [11, 12]. The gene discussed is IL6R; the disease is Gilbert syndrome.